Endocrinoloxía e nutrición
Servicio
Hospital Universitario de la Princesa
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario de la Princesa (34)
2024
-
Current barriers to initiating insulin therapy in individuals with type 2 diabetes
Frontiers in Endocrinology, Vol. 15
-
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs
Endocrine-related cancer
-
Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion
European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466
-
Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs
Endocrine-Related Cancer, Vol. 31, Núm. 7
-
Prognostic Value of D-dimer to Lymphocyte Ratio (DLR) in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients: A Validation Study in a National Cohort
Viruses, Vol. 16, Núm. 3
2023
-
Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
Frontiers in Endocrinology, Vol. 14
2022
-
Acromegaly disease activity according to ACRODAT®, a cross-sectional study in Spain: ACROVAL study
Endocrine, Vol. 75, Núm. 2, pp. 525-536
2021
-
Pasireotide in the Personalized Treatment of Acromegaly
Frontiers in Endocrinology, Vol. 12
2020
-
Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
Endocrine, Vol. 70, Núm. 3, pp. 575-583
-
Home and Ambulatory Artificial Nutrition (NADYA) group report. Home parenteral nutrition in Spain, 2018
Nutricion Hospitalaria, Vol. 37, Núm. 2, pp. 403-407
-
Lat-1 and glut-1 carrier expression and its prognostic value in gastroenteropancreatic neuroendocrine tumors
Cancers, Vol. 12, Núm. 10, pp. 1-18
2019
-
ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly
Endocrinologia, Diabetes y Nutricion, Vol. 66, Núm. 5, pp. 320-329
2018
-
Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors
Scientific Reports, Vol. 8, Núm. 1
-
Expert document on management of acromegaly
Endocrinologia, Diabetes y Nutricion, Vol. 65, Núm. 8, pp. 428-437
-
Home and ambulatory artificial nutrition (NADYA) report. home parenteral nutrition in Spain, 2017
Nutricion Hospitalaria, Vol. 35, Núm. 6, pp. 1491-1496
2017
-
Prevalence of acromegaly in patients with symptoms of sleep apnea
PLoS ONE, Vol. 12, Núm. 9
2016
-
Genetic Predictors of Response to Different Medical Therapies in Acromegaly
Progress in Molecular Biology and Translational Science (Elsevier B.V.), pp. 85-114
-
Long-term treatment with pegvisomant for acromegaly: A 10-year experience
Clinical Endocrinology, Vol. 84, Núm. 4, pp. 540-550
-
Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY
Pituitary, Vol. 19, Núm. 2, pp. 127-137
-
Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study
Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 63, Núm. 8, pp. 397-408